01Form
What form is produced?
A flowable injectable preparation and a solid clot or membrane are distinct outputs.
PRF · Autologous Platelet Concentrates · Istanbul
PRF · Autologous Platelet Concentrates · Istanbul
PRF and Autologous Platelet Concentrates
PRF refers to autologous blood preparations in which fibrin formation is central to the final material. Injectable liquid, clot and membrane forms have different handling and cannot be treated as one product.
PRF is not simply another name for PRP. Many protocols allow clotting to begin without added anticoagulant, making the tube, centrifugal force, timing and intended form part of the product identity.
Quick Orientation
Four product questions
PRF is understood through form, process, target and timing.
Abbreviations such as i-PRF do not make protocols comparable. The actual material and the clinical question must both be defined.
02Process
How is it produced?
Tube material, additives, blood volume, rotor, force, duration and selected layer are recorded.
03Indication
Why is it considered?
A confirmed hair diagnosis and scalp target are separated from other tissue uses.
04Control
When is it reviewed?
A predefined clinical endpoint and follow-up interval guide any later decision.
What PRF Means
Autologous product family · fibrin formation
PRF describes several fibrin-rich preparations, not one standard concentrate.
Platelet-rich fibrin is produced as blood coagulates into a fibrin-containing structure. Cellular content, consistency and usable time vary with the complete protocol.
What it may provide
- Provide an autologous preparation in a defined liquid or solid form
- Contain platelets, white cells and fibrin in protocol-dependent proportions
- Be considered for a diagnosed local target with documented handling
- Support separate review of procedure tolerance and the chosen hair endpoint
What it does not prove
- Diagnose the reason for hair loss
- Be substituted for PRP evidence or treated as the same product
- Guarantee hair growth, density or lasting change
- Establish superiority from a brand name or centrifuge setting alone
Fibrin formation and autologous origin do not establish effectiveness or safety. Product form, indication, administration and evidence remain separate questions.
Medical Suitability
Indication and product form together
Five checks come before a PRF preparation is selected.
Personal assessment connects the hair diagnosis, scalp anatomy, blood-related factors, intended form and a measurable follow-up point.
- 01
Confirm the hair diagnosis
Pattern, activity, previous treatment and signs of inflammatory or scarring disease are reviewed.
- 02
Examine the scalp target
Skin integrity, infection, inflammation, scarring and the proposed delivery area are assessed.
- 03
Review blood and medicines
Relevant blood findings, bleeding history, medicines and healing factors are considered.
- 04
Choose form only if justified
Liquid or solid PRF, delivery route and timing follow the indication rather than preference.
- 05
Define the endpoint
The baseline, image standard, review time and stopping criteria are recorded before treatment.
Preparation and Use
Tube · relative force · clotting window
For PRF, timing is part of the product.
Rotor geometry, relative centrifugal force, duration and the interval before use influence the material. Revolutions per minute alone are not an adequate description.
01Collection
Match blood to the intended system
The sample is collected for the individual in a tube selected for the planned preparation.
- Record identity and collection time
- Name the tube and any additive
- Review relevant clinical factors
02Separation
Record force and selected layer
The complete centrifugation route determines the cellular and fibrin-containing fraction.
- Record rotor and relative force
- Document duration and harvest layer
- Identify form and usable volume
03Use
Coordinate clotting with delivery
A liquid preparation is used within its planned working window; solid forms keep a different role.
- Confirm sterility and route
- Define the scalp target
- Record timing and immediate response
A lower-force protocol, a trademark or the initials PRF do not establish superiority. A reproducible process must suit the target and the intended material form.
Evidence and Limits
Small studies · variable products
PRF evidence remains early and product-specific.
Recent clinical reports include injectable PRF for pattern hair loss, but many are small, uncontrolled or use proprietary preparations and short follow-up.
Separate study designs
Case series, before-and-after cohorts and controlled trials do not provide the same certainty.
Separate product forms
Liquid injectable PRF data cannot establish outcomes for a clot, membrane or another blood concentrate.
Do not borrow PRP evidence
Different clotting, fibrin structure and cellular distribution prevent automatic transfer of PRP findings.
Keep long-term questions open
Durability, ideal repetition and comparative value against established options remain uncertain.
PRF does not receive automatic priority over PRP, diagnosis-led treatment, observation, surgery or no intervention.
Individual Treatment Plan
Form before frequency
A PRF plan starts with a defined product and a defined question.
Possible applications are not sold as a fixed series. Indication, form, process, tolerability and objective review determine each step.
Record the baseline
Document diagnosis, scalp target, current treatment, images and the precise PRF form.
Limit the initial decision
Give any first phase one purpose, one reproducible protocol and one review date.
Review the right outcome
Separate early fibrin-related changes from the later hair endpoint.
Reassess continuation
Further use, combination, pause or stopping requires a new documented reason.
Course and Follow-Up
Local response · fibrin behaviour · hair endpoint
An early firmness or injection response is not a hair result.
Immediate tissue response, later scalp recovery and a possible hair change are reviewed on separate timescales.
- 01Early
Hours to days
Tenderness, redness, swelling, bruising or temporary firmness may follow injection.
- 02Healing
Days to weeks
Persistent or increasing local changes need assessment rather than being attributed to fibrin automatically.
- 03Hair endpoint
Following months
Hair photographs and any agreed measurements are repeated under comparable conditions.
- 04Decision
At the review point
Safety, objective findings, effort and alternatives determine whether the plan changes or ends.
Risks and Alternatives
Autologous · fibrin-forming · still invasive
Product form and target anatomy influence the risk profile.
Consent covers collection, processing, injection, personal blood-related factors and the option not to proceed.
01Collection and injection
Procedure-related
Pain, bleeding, bruising, swelling, infection and persistent local symptoms are possible.
02Fibrin form
Product and region
Temporary firmness may occur; a painful, enlarging or persistent lump requires medical review.
03Clinical priority
Patient and alternatives
Blood findings, medicines, active illness and more established treatment pathways can change the decision.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Unexpected or worsening symptoms after injection require timely in-person assessment; remote messages cannot determine tissue findings.
Istanbul and Follow-Up
Time-sensitive preparation · planned review
PRF cannot be separated from examination and documentation.
For international patients, the clinical indication, possible preparation, aftercare and later review form one pathway.
01Before travel
Organise the clinical question
Current diagnosis and treatment history help identify what needs personal examination.
02Bağdat Caddesi
Confirm form and indication
The scalp target, blood-related factors, alternatives and proposed PRF form are reviewed.
03Treatment day
Document the time chain
If suitable, collection, centrifugation, product form, use and immediate response are recorded.
04After return
Agree the later endpoint
Aftercare, warning signs and a comparable hair review are planned before return.
The Doctor Aslan Approach
Product identity · clinical boundary
The prepared material matters more than the abbreviation.
PRF is not presented as a natural cure or as automatically better than PRP. The decision rests on diagnosis, form, process, target and follow-up.
Start with the indication
The hair diagnosis and scalp findings come before a blood-product choice.
Keep timing traceable
Tube, force, duration, harvested layer, form and time to use remain documented.
Keep PRF and PRP separate
Product data and clinical evidence are not exchanged between the two.
Set a stopping rule
Continuation requires a fresh assessment of benefit, burden, uncertainty and alternatives.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about PRF; no personal diagnosis or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is PRF and Autologous Platelet Concentrates?+
PRF and Autologous Platelet Concentrates is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for PRF and Autologous Platelet Concentrates?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Identify the form · confirm the indication